Evidence map›Paper›PMID 27510552›Full record

ArticleAnalytical biochemistry2016

Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuous scattering.

Gregory V Barnett, Michael Drenski, Vladimir Razinkov, Wayne F Reed, Christopher J Roberts

Abstract read
In one paragraph

Article in Analytical biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Protein aggregation and immunogenicity of biotherapeutics.International journal of pharmaceutics · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Gregory V BarnettDepartment of Chemical & Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
Michael DrenskiDepartment of Physics, Tulane University, New Orleans, LA 70118, USA.
Vladimir RazinkovDrug Product Development, Amgen, Thousand Oaks, CA 91320, USA.
Wayne F ReedDepartment of Physics, Tulane University, New Orleans, LA 70118, USA. Electronic address: wreed@tulane.edu.
Christopher J RobertsDepartment of Chemical & Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA. Electronic address: cjr@udel.edu.
Tulane University · USUniversity of Delaware · USAmgen (United States) · US

Funding

Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic ProteinsR01EB006006 · NIBIB · UNIVERSITY OF COLORADO · PI RANDOLPH, THEODORE W · 2006 to 2017
$7.2M
NIBIB NIH HHS R01 EB006006
6 · The paper itself

Abstract

Parallel temperature initial rates (PTIR) from chromatographic separation of aggregating protein solutions are combined with continuous simultaneous multiple sample light scattering (SMSLS) to make quantitative deductions about protein aggregation kinetics and mechanisms. PTIR determines the rates at which initially monomeric proteins are converted to aggregates over a range of temperatures, under initial-rate conditions. Using SMSLS for the same set of conditions provides time courses of the absolute Rayleigh scattering ratio, IR(t), from which a potentially different measure of aggregation rates can be quantified. The present report compares these measures of aggregation rates across a range of solution conditions that result in different aggregation mechanisms for anti-streptavidin (AS) immunoglobulin gamma-1 (IgG1). The results illustrate how the two methods provide complementary information when deducing aggregation mechanisms, as well as cases where they provide new mechanistic details that were not possible to deduce in previous work. Criteria are presented for when the two techniques are expected to give equivalent results for quantitative rates, the potential limitations when solution non-idealities are large, as well as a comparison of the temperature dependence of AS-IgG1 aggregation rates with published data for other antibodies.

Indexed as

LightModels, ChemicalProtein AggregatesScattering, RadiationAnimalsImmunoglobulin GMiceStreptavidinImmunoglobulin GProtein AggregatesStreptavidinAggregation mechanismsAggregation ratesLaser scatteringProtein stability

Identifiers

PMID27510552
PMCPMC5004974
OpenAlexW2507122620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.